KIT and neoplasm: However, in 2005, Felli's group [16] discovered that KIT, a well-known oncogene, is targeted by miR-221/222 in erythroblastic leukemia, thus illustrating miR-221/222's function as a tumor suppressor in human erythroblast cells.